Remarkably, our study suggests that PARP and the nucleolus may be the dual targets for PARPi, and that these agents could be used in tumors with HRD and/or active ribosome biogenesis. Here, PARP1 is linked to hypoparathyroidism-retardation-dysmorphism syndrome.